Overview of Non-clinical Assessment in Drug Development (8/14) REdI 2017
Рет қаралды 15,991
4 жыл бұрынHanan Ghantous covers the role and responsibilities of the pharmacology/toxicology reviewer related to the various components of the Investigational New Drug (IND) phase of drug development. This presentation covers both scientific and regulatory pharmacology/toxicology concepts that are part of the non-clinical submission to an IND/ NDA/BLA. Viewers will gain an understanding of animal studies submitted to support the safety of clinical studies and marketing applications.
-------------------------
FDA CDER’s Small Business and Industry Assistance (SBIA) educates and provides assistance in understanding the regulatory aspects of human drug products & clinical research.
Upcoming training and free continuing education credits: www.fda.gov/cd...
CDER SBIA 2017 Playlist: • 2017 CDER Small Busine...
LinkedIn: / cder-small-business-an...
Training resources: www.fda.gov/cd...
Twitter: / fda_drug_info
CDER small business e-mail update subscription: updates.fda.go...
Email: CDERSBIA@fda.hhs.gov
Phone: (301) 796-6707 I (866) 405-5367
U.S. Food and Drug Administration
Рет қаралды 6 М.
U.S. Food and Drug Administration
Рет қаралды 12 М.
Sergio Outdoors
Рет қаралды 34 МЛН
U.S. Food and Drug Administration
Рет қаралды 19 М.
U.S. Food and Drug Administration
Рет қаралды 22 М.
U.S. Food and Drug Administration
Рет қаралды 10 М.
U.S. Food and Drug Administration
Рет қаралды 11 М.
U.S. Food and Drug Administration
Рет қаралды 4,1 М.
U.S. Food and Drug Administration
Рет қаралды 27 М.
U.S. Food and Drug Administration
Рет қаралды 15 М.
U.S. Food and Drug Administration
Рет қаралды 10 М.
U.S. Food and Drug Administration
Рет қаралды 33 М.
U.S. Food and Drug Administration
Рет қаралды 12 М.